Crossposted from Nature’s news blog on behalf of Ewen Callaway

The biotechnology industry breathed a deep sign of relief today, as a US Appeals court upheld a company’s controversial patents on genes linked to breast cancer.

The US Federal Appeals Court in New York overturned a lower court’s ruling in a case pitting the genetics testing firm Myriad Genetics against a legion of plaintiffs concerned that the company’s patents on BRCA1 and BRCA2 are limiting the development of tests for breast and ovarian cancer and research into these conditions.

Continue reading on Nature’s news blog.